Trial
NCT02355431
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
Solid Tumors and Hematologic Malignancy
Intervention
Itacitinib
Why stopped
Study withdrawn before enrolling first patient
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-08